BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning.
Several other brokerages have also issued reports on RARE. ValuEngine upgraded Ultragenyx Pharmaceutical from a hold rating to a buy rating in a research report on Wednesday. Credit Suisse Group reaffirmed a hold rating and set a $59.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Raymond James lifted their price target on shares of Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the company a buy rating in a research note on Tuesday, November 6th. Canaccord Genuity decreased their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a buy rating for the company in a research note on Wednesday, November 7th. Finally, Citigroup raised shares of Ultragenyx Pharmaceutical from a sell rating to a neutral rating and lifted their price target for the company from $46.00 to $54.00 in a research note on Thursday, November 8th. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $76.56.
Shares of NASDAQ:RARE opened at $59.82 on Wednesday. Ultragenyx Pharmaceutical has a 1 year low of $37.44 and a 1 year high of $90.98.
In related news, Director William Aliski sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $49.69, for a total value of $298,140.00. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at $3,607,990.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.40% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Capital Research Global Investors raised its stake in Ultragenyx Pharmaceutical by 1.7% in the third quarter. Capital Research Global Investors now owns 5,856,138 shares of the biopharmaceutical company’s stock worth $447,058,000 after buying an additional 100,575 shares in the last quarter. BlackRock Inc. raised its stake in Ultragenyx Pharmaceutical by 2.8% in the fourth quarter. BlackRock Inc. now owns 4,476,812 shares of the biopharmaceutical company’s stock worth $194,652,000 after buying an additional 123,409 shares in the last quarter. Capital International Investors raised its stake in Ultragenyx Pharmaceutical by 20.9% in the third quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock worth $332,834,000 after buying an additional 755,127 shares in the last quarter. Federated Investors Inc. PA raised its stake in Ultragenyx Pharmaceutical by 4.7% in the third quarter. Federated Investors Inc. PA now owns 1,484,271 shares of the biopharmaceutical company’s stock worth $113,309,000 after buying an additional 66,720 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in Ultragenyx Pharmaceutical by 16.5% in the fourth quarter. First Trust Advisors LP now owns 1,471,934 shares of the biopharmaceutical company’s stock worth $64,000,000 after buying an additional 208,468 shares in the last quarter. 98.35% of the stock is owned by institutional investors.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Further Reading: NASDAQ Stock Market Explained
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.